July 12th 2016: Encore: Summit Therapeutics: Ridinilazole, A Microbiome Preserving Antibiotic For The Treatment Of a C. difficile Infection |eCard

TROUBLE VIEWING? Click Here to view the Promo card on the web

SIGN-UP NOW! Click to become a Member for Free!

C. diff. Spores and More

Tuesday at 10 AM Pacific

July 12th 2016: Encore: Summit Therapeutics: Ridinilazole, A Microbiome Preserving Antibiotic For The Treatment Of a C. difficile Infection

Join us as we discuss a promising and new treatment for a C. difficile infection. Summit Therapeutic's Ridinilazole, a microbiome preserving antibiotic will be introduced with updates by our two guests Dr. Kevin W. Garey, Chair, Department of Pharmacy Practice and Translational Research, Professor of Pharmacy Practice at the University of Houston College of Pharmacy, Houston, Texas and Dr. Richard Vickers, Chief Scientific Officer at Summit Therapeutics..

DOWNLOAD PDF

Tune in

Tuesday at 10 AM Pacific Time on VoiceAmerica Health and Wellness Channel

LISTEN LIVE

EPISODE ON DEMAND

VIEW HOST PAGE

Questions? Comments?
Call In Live! Call-In
Toll Free: 1-866-472-5792
Intl: 001-480-553-5759

Featured Guests

Dr Kevin W Garey, PharmD, MS, FASHP

Chair, Department of Pharmacy Practice and Translational Research Professor of Pharmacy Practice at the University of Houston College of Pharmacy, Houston, Texas Kevin Garey, Pharm.D., M.S., is Chair of the Department of Clinical Sciences and Administration and Professor of Pharmacy Practice at the University of Houston College of Pharmacy in Houston, Texas.

Read more

Richard Vickers Ph.D.

Dr. Vickers is Chief Scientific Officer, Antimicrobials and Programme Lead for CDI, Summit Therapeutics. He joined Summit in 2003 and during his time has worked in a variety of roles involved in the development and management of various antibacterial therapeutic programs.

Read more

Share This Episode

Share On Facebook

Share On Twitter

Share On LinkedIn

Connect with VoiceAmerica

Download our mobile apps